Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
Healthcare
$11.79 +2.66%
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
52W Low $18.50High $28.23
Volume 0.42M
Average 0.80M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$158.34M
FY 2025 · Annual
Net Income
-$148.96M
FY 2025 · Annual
Income Statement
USD
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 109.11M |
| Selling, General & Admin | 49.23M |
| Operating Expenses | 158.34M |
| Depreciation & Amortization | 310K |
| EBITDA | (158.03M) |
| EBITDA Margin | — |
| Operating Income | (158.34M) |
| Operating Margin | — |
| Interest Income | 11.05M |
| Interest Expense | 0 |
| Other Income / Expenses | 9.39M |
| Income Before Tax | (148.96M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (148.96M) |
| Net Margin | — |
| EPS (Basic) | (1.26) |
| EPS (Diluted) | (1.26) |
| 117.95M | |
| 117.95M |
KLRA Earnings Waterfall · TTM
NASDAQ:KLRA · Revenue to Net Income
No earnings data available.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 9, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 |
How much revenue does KLRA generate?
Kailera Therapeutics, Inc. (KLRA) reported $0.00 of revenue in fiscal 2025.
Is KLRA profitable?
Kailera Therapeutics, Inc. (KLRA) reported -$148.96M of net income.
Continue the stock analysis
Jump to another research area for this company.